Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use)

产品名称	Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use)
目录号	NBR-0740
别名	T200; GP180; CD45; LCA; IMD105; B220
外观	Transparent Liquid
分子量	150kDa
CAS	N/A
溶解度	Water, PBS, TBS Buffer,etc.
存储条件	Temp. -80℃
保存时间	see COA
备注1	CHO Expressed
备注2	Ab. Isotype - IgG

目录号	规格	价格	库存状态
NBR-0740-100UG	100ug	￥550	请咨询
NBR-0740-1MG	1mg	￥3500	请咨询
NBR-0740-5MG	5mg	￥7500	请咨询

【产品概况】

产品名称：Human PTPRC / CD45 Antibody (Novartis patent anti-CD45, Research Use)
产品编号：NBR-0740
针对靶点：PTPRC / CD45
抗体药商品名：Novartis patent anti-CD45
抗体药描述：The drug is a recombinant fully human anti-CD45 monoclonal antibody, being developed by Novartis.

【产品参数】

产品外观：Transparent Liquid
分子量：~150kDa
CAS：N/A
溶解度：Water; PBS, TBS Buffer等
表达系统：CHO Expressed
抗体亚型：Ab. Isotype - IgG

【基因信息】

Gene Name: PTPRC
Synonyms: T200; GP180; CD45; LCA; IMD105; B220
Target Description: Protein tyrosine-protein phosphatase required for T-cell activation through the antigen receptor. Acts as a positive regulator of T-cell coactivation upon binding to DPP4. The first PTPase domain has enzymatic activity, while the second one seems to affect the substrate specificity of the first one. Upon T-cell activation, recruits and dephosphorylates SKAP1 and FYN.
Ensembl: ENSG00000081237
Uniprot: P08575